Montelukast, an asthma drug, can bind to and block a crucial SARS-CoV-2 protein. This discovery sets the stage for a new class of antiviral drugs, designed to target and interfere with the virus' immunosuppressive tactics.
Subscribe to:
Post Comments (Atom)
< + > Beyond the Science by Gary Zammit – Life Sciences Today Podcast Episode 46
We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Gary Zammit, PhD,...
-
As I’m sure you know, times are tough. Wages have largely remained the same while prices have risen across the board – and healthcare is no ...
-
Solution Erases Long Phone Holds for Patients, Supports Overwhelmed Medical Front Desk Workers, and Improves Patient Access to Physicians A...
-
Announcement written by Zack Kanter, Founder and CEO at Stedi In February of last year, I gathered our engineering team in a war room. Chan...
No comments:
Post a Comment